Here is a scenario we encounter regularly. A sponsor has a promising biologic, a T cell-engaging bispecific, a Treg-depleting antibody, or a checkpoint inhibitor with a novel target. The tox species are cynomolgus macaque, minipig, or dog. And the clinical team wants to know: what will we actually see…